These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 19689285

  • 1. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M, Moretti L, Lu B.
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [Abstract] [Full Text] [Related]

  • 2. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ, Margaritis LH, Voutsinas GE.
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [Abstract] [Full Text] [Related]

  • 3. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N.
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [Abstract] [Full Text] [Related]

  • 4. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
    Maloney A, Workman P.
    Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
    [Abstract] [Full Text] [Related]

  • 5. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 6. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y.
    Curr Pharm Des; 2005 Aug; 11(9):1131-8. PubMed ID: 15853661
    [Abstract] [Full Text] [Related]

  • 7. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J, Eichner S, Zeilinger C, Kirschning A.
    Nat Prod Rep; 2013 Oct 11; 30(10):1299-323. PubMed ID: 23934201
    [Abstract] [Full Text] [Related]

  • 8. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
    Blagg BS, Kerr TD.
    Med Res Rev; 2006 May 11; 26(3):310-38. PubMed ID: 16385472
    [Abstract] [Full Text] [Related]

  • 9. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV, Workman P.
    Endocr Relat Cancer; 2006 Dec 11; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [Abstract] [Full Text] [Related]

  • 10. Macrocyclic inhibitors of hsp90.
    Johnson VA, Singh EK, Nazarova LA, Alexander LD, McAlpine SR.
    Curr Top Med Chem; 2010 Dec 11; 10(14):1380-402. PubMed ID: 20536417
    [Abstract] [Full Text] [Related]

  • 11. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C, Lang SA, Stoeltzing O.
    Anticancer Res; 2009 Jun 11; 29(6):2031-42. PubMed ID: 19528462
    [Abstract] [Full Text] [Related]

  • 12. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV, Younes A.
    Future Oncol; 2005 Apr 11; 1(2):273-81. PubMed ID: 16555999
    [Abstract] [Full Text] [Related]

  • 13. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
    Hadden MK, Lubbers DJ, Blagg BS.
    Curr Top Med Chem; 2006 Apr 11; 6(11):1173-82. PubMed ID: 16842154
    [Abstract] [Full Text] [Related]

  • 14. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z, Jia L, Wang J, Wu X, Shi G, Lu C, Shen Y.
    Chem Biol Drug Des; 2015 Feb 11; 85(2):181-8. PubMed ID: 24903735
    [Abstract] [Full Text] [Related]

  • 15. Hsp90: an emerging target for breast cancer therapy.
    Beliakoff J, Whitesell L.
    Anticancer Drugs; 2004 Aug 11; 15(7):651-62. PubMed ID: 15269596
    [Abstract] [Full Text] [Related]

  • 16. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L, Wang L, You QD, Xu XL.
    J Med Chem; 2020 Mar 12; 63(5):1798-1822. PubMed ID: 31663736
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
    Li YP, Chen JJ, Shen JJ, Cui J, Wu LZ, Wang Z, Li ZR.
    Cancer Chemother Pharmacol; 2015 Apr 12; 75(4):773-82. PubMed ID: 25681003
    [Abstract] [Full Text] [Related]

  • 18. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P.
    Trends Mol Med; 2004 Feb 12; 10(2):47-51. PubMed ID: 15106614
    [Abstract] [Full Text] [Related]

  • 19. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P, Burrows F, Neckers L, Rosen N.
    Ann N Y Acad Sci; 2007 Oct 12; 1113():202-16. PubMed ID: 17513464
    [Abstract] [Full Text] [Related]

  • 20. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z, Peng R, Li Z, Wang Y, Lu C, Shen Y, Wang J, Shi G.
    Int J Mol Med; 2015 Aug 12; 36(2):424-32. PubMed ID: 26059743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.